Jonathan Wolleben
Stock Analyst at Citizens JMP
(4.87)
# 332
Out of 4,455 analysts
789
Total ratings
52.7%
Success rate
21.8%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintained: Buy | $132 → $146 | $123.77 | +17.96% | 32 | Jun 15, 2026 | |
| SGMT Sagimet Biosciences | Maintained: Buy | $35 → $12 | $7.06 | +69.97% | 21 | May 19, 2026 | |
| ALT Altimmune | Maintained: Buy | $14 → $11 | $2.82 | +290.07% | 81 | May 14, 2026 | |
| SPRB Spruce Biosciences | Maintained: Buy | $170 → $150 | $55.11 | +172.18% | 28 | May 14, 2026 | |
| IRD Opus Genetics | Maintained: Buy | $12 → $11 | $4.00 | +175.00% | 2 | May 13, 2026 | |
| KLRS Kalaris Therapeutics | Maintained: Buy | $26 → $25 | $4.32 | +478.70% | 3 | May 13, 2026 | |
| PHVS Pharvaris | Maintained: Buy | $52 → $74 | $34.01 | +117.58% | 34 | May 13, 2026 | |
| MBX MBX Biosciences | Maintained: Buy | $61 → $86 | $52.31 | +64.40% | 4 | May 12, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintained: Buy | $97 → $95 | $36.70 | +158.86% | 48 | May 8, 2026 | |
| BCRX BioCryst Pharmaceuticals | Maintained: Buy | $25 → $28 | $9.94 | +181.69% | 49 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $120 → $137 | $121.88 | +12.41% | 36 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $9 | $1.32 | +581.82% | 1 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $47 → $55 | $16.01 | +243.54% | 44 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $176 → $152 | $109.84 | +38.38% | 21 | Mar 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $1.53 | +422.88% | 42 | Mar 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $120 → $113 | $49.71 | +127.32% | 25 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $63 | $42.18 | +49.36% | 1 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $9.84 | - | 63 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.9435 | - | 5 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $527 → $745 | $512.65 | +45.32% | 61 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 → $11 | $5.90 | +86.44% | 17 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $3.66 | +391.80% | 41 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 → $4 | $0.6799 | +488.32% | 7 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.195 | - | 53 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $7.00 | n/a | 27 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $16.00 | n/a | 42 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $24 | $26.98 | n/a | 1 | May 12, 2023 |
Mirum Pharmaceuticals
Jun 15, 2026
Maintained: Buy
Price Target: $132 → $146
Current: $123.77
Upside: +17.96%
Sagimet Biosciences
May 19, 2026
Maintained: Buy
Price Target: $35 → $12
Current: $7.06
Upside: +69.97%
Altimmune
May 14, 2026
Maintained: Buy
Price Target: $14 → $11
Current: $2.82
Upside: +290.07%
Spruce Biosciences
May 14, 2026
Maintained: Buy
Price Target: $170 → $150
Current: $55.11
Upside: +172.18%
Opus Genetics
May 13, 2026
Maintained: Buy
Price Target: $12 → $11
Current: $4.00
Upside: +175.00%
Kalaris Therapeutics
May 13, 2026
Maintained: Buy
Price Target: $26 → $25
Current: $4.32
Upside: +478.70%
Pharvaris
May 13, 2026
Maintained: Buy
Price Target: $52 → $74
Current: $34.01
Upside: +117.58%
MBX Biosciences
May 12, 2026
Maintained: Buy
Price Target: $61 → $86
Current: $52.31
Upside: +64.40%
Crinetics Pharmaceuticals
May 8, 2026
Maintained: Buy
Price Target: $97 → $95
Current: $36.70
Upside: +158.86%
BioCryst Pharmaceuticals
May 7, 2026
Maintained: Buy
Price Target: $25 → $28
Current: $9.94
Upside: +181.69%
May 6, 2026
Maintained: Buy
Price Target: $120 → $137
Current: $121.88
Upside: +12.41%
May 5, 2026
Initiated Coverage: Buy
Price Target: $9
Current: $1.32
Upside: +581.82%
May 1, 2026
Maintained: Buy
Price Target: $47 → $55
Current: $16.01
Upside: +243.54%
Mar 17, 2026
Maintained: Buy
Price Target: $176 → $152
Current: $109.84
Upside: +38.38%
Mar 12, 2026
Reiterated: Buy
Price Target: $8
Current: $1.53
Upside: +422.88%
Feb 27, 2026
Maintained: Buy
Price Target: $120 → $113
Current: $49.71
Upside: +127.32%
Feb 24, 2026
Initiated Coverage: Buy
Price Target: $63
Current: $42.18
Upside: +49.36%
Feb 17, 2026
Maintained: Buy
Price Target: n/a
Current: $9.84
Upside: -
Jan 29, 2026
Downgraded: Hold
Price Target: n/a
Current: $0.9435
Upside: -
Jan 20, 2026
Maintained: Buy
Price Target: $527 → $745
Current: $512.65
Upside: +45.32%
Oct 23, 2025
Maintained: Buy
Price Target: $8 → $11
Current: $5.90
Upside: +86.44%
Oct 6, 2025
Reiterated: Buy
Price Target: $18
Current: $3.66
Upside: +391.80%
Oct 6, 2025
Maintained: Buy
Price Target: $15 → $4
Current: $0.6799
Upside: +488.32%
Jul 17, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.195
Upside: -
May 23, 2025
Reiterated: Buy
Price Target: $19
Current: $7.00
Upside: n/a
Apr 23, 2025
Reiterated: Hold
Price Target: n/a
Current: $16.00
Upside: n/a
May 12, 2023
Maintained: Buy
Price Target: $24
Current: $26.98
Upside: n/a